Sumitomo announces first patient dosed with TP-1454 : result awaited


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Sumitomo announces first patient dosed with TP-1454 : result awaited
Sumitomo Dainippon Pharma Oncology announces first patient dosed with TP-1454 in patients with advanced solid tumours

Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, announced that the first patient has been dosed with TP-1454, an investigational small-molecule pyruvate kinase M2 isoform (PKM2) activator, administered alone and in combination with ipilimumab and nivolumab, in a Phase 1/1b study in patients with advanced metastatic or progressive solid tumours.

"Dosing the first patient in this study marks an important milestone, as TP-1454 is the first PKM2 activator to be evaluated in patients with cancer," said Patricia S. Andrews, Chief Executive Officer and Global Head of Oncology, Sumitomo Dainippon Pharma Oncology (SDP Oncology). "The novel mechanism of action for TP-1454 aims to target the underlying drivers of tumour growth and tumour-driven immune suppression. We look forward to further understanding the safety and efficacy of TP-1454 alone and in combination in patients with solid tumours and applying these learnings to advance the compound."

The primary objectives of the first-in-human, open-label study are to assess the safety of oral TP-1454 administered once daily as monotherapy in patients with advanced metastatic or progressive solid tumours and as combination therapy with ipilimumab and nivolumab. The study will also establish the dose of TP-1454 alone and in combination with ipilimumab and nivolumab for future studies in select advanced solid tumours. Secondary objectives include assessing the pharmacokinetic (PK) profile and preliminary antitumor activity of TP-1454 alone and in combination with ipilimumab and nivolumab and evaluating pharmacodynamics of TP-1454.

TP-1454 is an investigational oral pyruvate kinase M2 isoform (PKM2) activator, that is currently being evaluated in a Phase 1/1b study in patients with advanced metastatic or progressive solid tumours. TP-1454 is the first PKM2 activator to be evaluated in cancer patients. Pyruvate kinase is the enzyme responsible for catalyzing the last step of glycolysis. PKM2 plays a critical role in the metabolic changes observed in cancer and immune cells and establishes a metabolic advantage for tumour cells over the tumour immune microenvironment.1

Tags : #SumitomoDainipponPharmaOncologyInc #LatestPharmaNews10thOct #LatestNewsonCancerTreatment10thoct #PatriciaSAndrews #CancerPatients

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026